US FDA Should Take Its Time With COVID Vaccine BLAs

 
• By Michael McCaughan

Agency is pledging to act well ahead of the six-month review deadline in reviewing full applications for COVID 19 vaccines that are already authorized for emergency use. Going too fast may be counterproductive, in more ways than one.

Speeding the full BLA review of the COVID vaccines would be counterproductive, the author argues. • Source: Design by Nielsen Hobbs

More from Vaccines

More from Pink Sheet